Carol Hsing Miao

Title: Carol Hsing Miao: Innovator in Gene Therapy

Introduction

Carol Hsing Miao is a prominent inventor based in Seattle, WA, known for her groundbreaking work in gene therapy. She has made significant contributions to the field, particularly in developing methods to treat blood clotting disorders such as hemophilia A. Her innovative approach combines advanced techniques in gene delivery and immunology.

Latest Patents

Carol Hsing Miao holds a patent for her invention titled "Vivo gene therapy using intraosseous delivery of a lentiviral gene construct." This patent outlines methods, compositions, and systems designed to treat subjects in need of plasma Factor VIII, especially those with preexisting anti-FVIII inhibitory antibodies. The methods involve administering a therapeutically effective amount of an inflammation suppressor, a CD8+ T cell depleting agent, and a composition comprising a lentiviral vector linked to a megakaryocyte-specific promoter. This innovative approach is particularly useful for treating individuals with blood clotting disorders.

Career Highlights

Carol is affiliated with Seattle Children's Hospital, where she continues to advance her research and clinical applications in gene therapy. Her work has garnered attention for its potential to improve treatment outcomes for patients suffering from hemophilia A and similar conditions.

Collaborations

Throughout her career, Carol has collaborated with esteemed colleagues, including David J Rawlings and Chong Li. These partnerships have further enriched her research and contributed to the development of effective therapeutic strategies.

Conclusion

Carol Hsing Miao is a trailblazer in the field of gene therapy, with a focus on innovative solutions for blood clotting disorders. Her contributions are paving the way for new treatment options that could significantly enhance patient care.